Swedish Orphan gains Korean partner for two products
This article was originally published in Scrip
Swedish Orphan Biovitrum (Sobi) has reached a deal for the distribution of two products for rare disorders in South Korea, linking up with the local firm BL&H for Orfadin (nitisone) and Kepivance (recombinant palifermin).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.